Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain to interfere with its homodimerization and suppress MyD88 signaling. TJ-M2010-5 can be used in myocardial ischemia/reperfusion injury studies.
説明 | TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain to interfere with its homodimerization and suppress MyD88 signaling. TJ-M2010-5 can be used in myocardial ischemia/reperfusion injury studies. |
In vitro | TJ-M2010-5 (0 μM, 5 μM, 10 μM, 20 μM and 30 μM) prevents B cell proliferation and induces B cells apoptosis after stimulation with R848 (500 ng/mL)[1]. |
In vivo | TJ-M2010-5 statistically significantly decreases TNF-α, IL-6, G-CSF, MIP-1β, IL-11, IL-17A, IL-22, and IL-23 serum concentrations in mice at both two and seven weeks postinduction. In a 10-week CAC mouse model, TJ-M2010-5 statistically significantly reduces AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, results in 0% mortality of treated mice, decreases cell proliferation, and increased apoptosis in colon tissue[2]. |
分子量 | 406.54 |
分子式 | C23H26N4OS |
CAS No. | 1357471-57-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (233.68 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TJ-M2010-5 1357471-57-8 Immunology/Inflammation MyD88 ischemia MIRI Anoxia factor injury reoxygenation inhibit reperfusion differentiation Inhibitor remodeling myocardial MyD88,TLR TJ-M-2010-5 myeloid TJM20105 TJ M2010 5 inhibitor